Trial reportThe Journal of urology2018
Impact of Potassium Citrate vs Citric Acid on Urinary Stone Risk in Calcium Phosphate Stone Formers.
Trial report in The Journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01754779 (Pharmacological Therapy for Calcium Phosphate Urolithiasis), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacological Therapy for Calcium Phosphate Urolithiasis
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Lime-based supplement reduces calcium oxalate stone recurrence: A multicenter randomized controlled trial.PloS one · 2025Trial
- Effects of a commercial lemonade beverage, potassium citrate, and combination therapy on urinary stone risk parameters in hypocitraturic stone formers: a randomized crossover trial.Translational andrology and urology · 2026Article
- Urolithiasis in patients with cancer.Nature reviews. Urology · 2026Review
- Long-term citrate treatment in high-risk kidney stone formers is not associated with metabolic adverse effects.Clinical kidney journal · 2026Article
- Calcium Phosphate Nephrolithiasis: A Comprehensive Review.Kidney medicine · 2026Review
- Hydroxycitrate is a Unique Inhibitor of Pathologically-Relevant Brushite Crystallization.ACS applied materials & interfaces · 2026Article
- Comparison of Thiazide Versus Alkali for Kidney Stone Recurrence Among Individuals With Hypocitraturia and High Urine pH.Kidney medicine · 2025Article
- In-vitro and In-silico evaluation of the inhibitory effects of Persea americana leaf extract against calcium oxalate stones.Urolithiasis · 2025Article
- Revisiting Uric Acid Stone Dissolution Kinetics: Insights for Optimizing Medical Therapy.European urology open science · 2025Article
- Balancing Stone Prevention and Kidney Function: A Therapeutic Dilemma.Journal of clinical medicine · 2025Review
- Mechanism ofDrug design, development and therapy · 2025Article
- Tartronic Acid as a Potential Inhibitor of Pathological Calcium Oxalate Crystallization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Urolithiasis in children; The importance of stone localization in treatment and follow-up.Urolithiasis · 2024Article
- Effects of two commercial diets and two supplements on urinary pH in dogs.Veterinary medicine and science · 2023Article
- A giant neobladder stone with insignificant symptoms: A case report and literature review.Frontiers in surgery · 2023Article
- Comparison of Empiric Preventative Pharmacologic Therapies on Stone Recurrence Among Patients with Kidney Stone Disease.Urology · 2022Article
- Comparison of Selective Versus Empiric Pharmacologic Preventative Therapy With Kidney Stone Recurrence.Urology · 2021Article
- Variability in stone composition and metabolic correlation between kidneys in patients with bilateral nephrolithiasis.International urology and nephrology · 2020Article
- Organic Acids from Roselle (Biomedicines · 2020Review
- Potassium citrate for stone prevention - Quantifying benefit through the number needed to treat: A narrative review.Urology annalsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo our knowledge no medication has been shown to be effective for preventing recurrent calcium phosphate urinary stones. Potassium citrate may protect against calcium phosphate stones by enhancing urine citrate excretion and lowering urine calcium but it raises urine pH, which increases calcium phosphate saturation and may negate the beneficial effects. Citric acid can potentially raise urine citrate but not pH and, thus, it may be a useful countermeasure against calcium phosphate stones. We assessed whether these 2 agents could significantly alter urine composition and reduce calcium phosphate saturation. MATERIALS AND
methodsIn a crossover metabolic study 13 recurrent calcium phosphate stone formers without hypercalciuria were evaluated at the end of 3, 1-week study phases during which they consumed a fixed metabolic diet and received assigned study medications, including citric acid 30 mEq twice daily, potassium citrate 20 mEq twice daily or matching placebo. We collected 24-hour urine specimens to perform urine chemistry studies and calculate calcium phosphate saturation indexes.
resultsUrine parameters did not significantly differ between the citric acid and placebo phases. Potassium citrate significantly increased urine pH, potassium and citrate compared to citric acid and placebo (p <0.01) with a trend toward lower urine calcium (p = 0.062). Brushite saturation was increased by potassium citrate when calculated by the relative supersaturation ratio but not by the saturation index.
conclusionsCitric acid at a dose of 60 mEq per day did not significantly alter urine composition in calcium phosphate stone formers. The long-term impact of potassium citrate on calcium phosphate stone recurrence needs to be studied further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.